The role of reactive drug metabolites in immune-mediated adverse drug reactions

Annals of Pharmacotherapy

Volumn 31, Issue 11, 1997, Pages 1378-1387

  Hess, David A ^a   Rieder, Michael J ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Adverse drug reactions; Hypersensitivity

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CYTOCHROME P450; DRUG METABOLITE; EPITOPE; HAPTEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; SULFONAMIDE;

CELL DAMAGE; CELLULAR IMMUNITY; COVALENT BOND; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MACROMOLECULE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030670372     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101116     Document Type: Review

References (56)

1. Weinshilboum RM. The therapeutic revolution. Clin Pharmacol Ther 1987;42:481-4.
2. Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hopitalized patients: excess length of stay, extra costs and attributable mortality. JAMA 1997;277:301-6.
3. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen MD, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277:307-11.
4. DeSwarte RD. Drug allergy: an overview. Clin Rev Allergy 1986;4:443-69.
5. Anderson JA, Atkinson NF Jr. Allergic reactions to drugs and biological agents. JAMA 1987;258:2891-9.
6. Patterson R, DeSwarte RD, Greenberger PA, Grammer LC. Drug allergy and protocols for management of drug allergies. N Engl Rev Allergy Proc 1986;35:1131-47.
7. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Saf 1994;11:196-212.
8. Cooke RA, Vander-Veer A. Human sensitization. J Immunol 1916;1: 201-6.
9. Park PK, Pirmohamed M. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992;122:456-9.
10. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Coombs RRA, Gell PGH, eds. Clinical aspects of immunology. 2nd ed. New York: FA Davis, 1968: 575-96.
11. Roitt I, Brostoff J, Male D. Hypersensitivity - types 1-4. In: Immunology. 2nd ed. London: Gower Medical Publishing, 1985:19.1-22.9.
12. Van Arsdell PP. Classification and risk factors for drug allergy. Immunol Allergy Clin North Am 1991;11:475-92.
13. Anderson JA. Allergic reactions to drugs and biological agents. JAMA 1992;268:2845-57.
14. Vervloet D, Pradal M, Charpin D, Porri F. Diagnosis of drug allergic reactions. Clin Rev Allergy Immunol 1995;13:265-80.
15. Rieder MJ. Immunopharmacology of adverse drug reactions. J Clin Pharmacol 1993;33:316-23.
16. Pirmohamed M, Madden S, Park BK. Idiosyncratic drug reactions: metabolic bioactivation as a pathogenic mechanism. Clin Pharmacokinet 1996;31:215-30.
17. Pohl LR, Satoh H, Christ DD, Kenna JG. The immunological and metabolic basis of drug hypersensitivities. Ann Rev Pharmacol 1988;28: 367-87.
18. Pirmohamed M, Kitteringham NR, Park BK. The role of active metabolites in drug toxicity. Drug Saf 1994;11:114-44.
19. Thrush MA, Mimnaugh EG, Gram TE. Activation of pharmacological agents to radical intermediates. Biochem Pharmacol 1982;31:3335-46.
20. Guengerich FP. Metabolic activation of carcinogens. Pharmacol Ther 1992;54:17-61.
21. Miller EC, Miller JA. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 1981;47:2327-45.
22. Prough RA, Spearman ME. Endogenous and dietary chemicals: metabolism and interaction with cytochrome P450. In: Guengerich FP, ed. Mammalian cytochromes P450, vol. 2. Boca Raton, FL: CRC Press, Inc., 1987:154-71.
23. Nelson SD. Molecular mechanisms of the hepatotoxicity cause by acetaminophen. Semin Liver Dis 1990;10:267-78.
24. Hinson JA. Biochemical toxicology of acetaminophen. Rev Biochem Toxicol 1980;2:103-29.
25. Park BK, Coleman JW, Kitteringham NR. Drug disposition and drug hypersensitivity. Biochem Pharmacol 1987;36:581-9.
26. Park BK, Kitteringham NR. Drug-protein conjugation and its immunological consequences. Drug Metab Rev 1990;22:87-104.
27. Weiss ME, Atkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy 1988;18:515-40.
28. Adelman D. Penicillin allergy. West Med J 1991;154:456-64.
29. Levine BB. Immunologic mechanisms of penicillin allergy: a haptenic model for the study of allergic diseases in man. N Engl J Med 1966;275: 1115-25.
30. Sullivan T, Wedner HJ, Shatz G, Yecies LD, Parker CW. Skin testing to detect penicillin allergy. J Allergy Clin Immunol 1981;68:171-80.
31. Alanis W, Weinstein AJ. Adverse reactions associated with the oral use of penicillins and cephalosporins. Med Clin North Am 1983;67:113-29.
32. Lovell SJ, Reid WD. Serum sickness with cefaclor (letter). Can Med Assoc J 1982;126:1032.
33. Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987;79:442-7.
34. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamide predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-84.
35. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro 'rechallenge' with hydroxylamine metabolites. Ann Intern Med 1989;110:286-9.
36. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1987;79:484-8.
37. Rieder MJ, Sisson E, Bird IA, Almawi WY. Proliferation of T-lymphocyte proliferation by sulphonamide hydroxylamines. Int J Immunopharmacol 1992;14:1175-80.
38. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of sulfamethoxazole reactive metabolites. J Pharmacol Exp Ther 1988;244:724-8.
39. 4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroylamine in human and rat microsomes. Drug Metab Dispos 1995;23:406-14.
40. Carr A, Tindall B, Penny R, Cooper DA. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 1993;94:21-5.
41. Leeder JS, Nakhooda A, Spielberg SP, Dosch HM. Cellular toxicity of sulfonamide reactive metabolites. II: Inhibition of natural killer cell activity in human peripheral blood mononuclear cells. Biochem Pharmacol 1991;41:575-9.
42. Meekins CV, Sullivan TJ, Gruschalla RS. Immunochemical analysis of sulfonamide drug allergy: identification of sulfamethoxazole-substituted human serum proteins. J Allergy Clin Immunol 1994;94:1017-28.
43. Marshall BE, Longnecker ED. General anesthetics. In: Limbird LE, Hardman JG, Molinoff PB, Budon RW, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: Pergamon Press, 1990:285-310.
44. Gut J, Christen U, Huwyler J. Mechanisms of halothane toxicity. Pharmacol Ther 1993;58:133-55.
45. Kenna JG, Neuberger J, Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988;8:1635-41.
46. Karasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevofluorane, isofluorane and methoxyfluorane. Anesthesiology 1993;79:795-807.
47. Shear NH, Spielberg SP, Cannon M, Miller M. Anticonvulsant hypersensitivity syndrome: in vitro risk assessment. J Clin Invest 1988;82: 1826-32.
48. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-7.
49. Strickler SM, Dansky LV, Miller MA, Seni MH, Anderman E, Spielberg SP. Genetic predisposition to phenytoin induced birth defects. Lancet 1982;2:746-9.
50. Dorman T. Toxicity of tricyclic antidepressants: are there important differences? J Intern Med Res 1985;13:77-83.
51. Rudorfer MV, Potts WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the "newer" versus "older" drugs. Drugs 1989;37:713-38.
52. Geneve J, Degott C, Letterson P. Metabolic activation of the tricyclic antidepressant amineptine. II: Protective role of glutathione against in vivo covalent binding. Biochem Pharmacol 1987;36:331-7.
53. Pirmohamed M, Kitteringham NR, Park BK. Idiosyncratic reactions to antidepressants: a review of the possible mechanisms and predisposing factors. Pharmacol Ther 1992;53:105-25.
54. Beckett AH, Al-Sarraj S. Metabolism of amitriptyline, nortriptyline, imipramine, and desipramine to yield hydroxylamines. J Pharm Pharmacol 1973;25:335-6.
55. Stein KM, Schlappner OL, Heaton CL, Decherd JW. Demonstration of basal cell immunofluorescence used in toxic epidermal necrolysis. Br J Dermatol 1972;86:246-52.
56. Lambert C, Park BK, Kitteringham NR. Activation of mianserin and its metabolites by human liver microsomes. Biochem Pharmacol 1989;38: 2853-8.